Randomized trial or the selective aromatase inhibitor formestane (Lentaron®) versus tamoxifen as first-line hormonal therapy in postmenopausal patients with advanced breast cancer
| Autor: | R. R. Santos, R. Peréz-Carrion, M. Fehling, C.M. Royce, R-Th. Michel, F. Calabresi, V. Alberola, P.F. Trunet |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Oncology
medicine.medical_specialty Aromatase inhibitor business.industry medicine.drug_class Advanced breast First line Cancer General Medicine medicine.disease Formestane law.invention Randomized controlled trial law Internal medicine medicine Hormonal therapy Surgery business Tamoxifen medicine.drug |
| Zdroj: | The Breast. 2:198-199 |
| ISSN: | 0960-9776 |
| DOI: | 10.1016/0960-9776(93)90119-z |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|